OUR TEAM

CEO

ERIC LEVIN

Eric Levin is a seasoned executive and serial entrepreneur who has created or managed products that have sold well in excess of $5 billion. He has been involved in more than 32 mergers and acquisitions and helped to grow several companies from startup through large-scale global success.

Eric joined Scripta because he believes the U.S. is in a healthcare crisis situation where drug prices are just too high and people cannot afford the medicine they need. He has turned his energy and expertise toward solving this crisis.

After beginning his career at a market-leading consumer electronics retailer, Eric joined Kevin O’Leary (of TV’s Shark Tank fame) in the consumer technology business as part of the executive management team responsible for growing The Learning Company from $60m to over $1.2 billion in sales in just six years, ultimately selling for $3.6 billion.

He has held several high-level roles at both large and small companies in both the consumer and the B2B space, including SVP, Mattel; Chief Marketing Officer, Frictionless Commerce; CEO & Co-President, Techno Source; and Division President and Corporate SVP, Li & Fung Ltd., a $20 billion publicly traded global company, and CEO of M5 Consulting, Inc.

CHIEF MEDICAL OFFICER

DR. PAUL S. BRADLEY

Dr. Bradley is a practicing board-certified Internist and co-founder and Chief Medical Officer of Scripta Insights. Scripta was born out of his frustration with the impact that the high costs of prescriptions were having on the health of his patients. As he discovered that physicians like him were blind to the real costs of prescription drugs, Dr. Bradley pulled together more than 50 practicing physicians to ﬁnd a solution for overspending on prescriptions.

In addition to seeing patients and overseeing Scripta’s P&T Committee, Dr. Bradley also serves as a Clinical Assistant Professor at Mercer Medical College and holds the title of principal investigator at Meridian Clinical Research in Savannah, GA. Dr. Bradley has led more than 100 pharmaceutical trials, including the Pfizer, Moderna and Novavax COVID-19 vaccine clinical trials. He had the distinct honor of dosing the first patient in Moderna’s Phase 2 trial and you may have even seen him on CNN when he dosed the first patient in their Phase 3 trial.

Dr. Bradley is a member of the American Medical Association, the American College of Physicians, the Georgia Medical Society, and is certified by the American Board of Internal Medicine. He is a Magna Cum Laude graduate of Tulane University and of the Emory School of Medicine.

CHIEF PHARMACY OFFICER

FERRIN WILLIAMS

As Scripta’s Chief Pharmacy Officer, Ferrin Williams leads the company’s clinical strategies organization responsible for devising innovative cost-containment strategies for prescription drugs, ensuring Scripta clients, members (and their providers) are provided with best-in-class clinical insights and tools.

With 15+ years’ experience in the pharmacy industry, Ferrin brings a unique perspective to Scripta that spans the retail pharmacy, pharmacy benefit manager (PBM) and broker/consulting sectors. Her expertise ranges from pharmacy operations and services to innovative clinical programs, pharmacy audit, alternative payer funding, and specialty drugs.

Ferrin earned her B.S., Doctor of Pharmacy and MBA degrees from the University of Oklahoma.

CHIEF REVENUE OFFICER

ANDREW BORDEN

Andrew Borden is Chief Revenue Officer at Scripta. He leads the company’s efforts to disrupt, transform and improve the $300 billion-a-year pharmacy benefit marketplace by working with payers, consultants, and HR executives at self-insured employers. Andrew has a diverse business background and provides his expertise in sales and business development to drive growth for the company and generate revenue.

After getting his start in investment banking and institutional equities, Andrew went on to lead sales and business development for internet and software companies, resulting in the successful sale of three companies. In 2001, he began investing directly in early and growth stage companies in industries including licensing, technology, entertainment and more.